Yellow fever vaccine

Generic name
Yellow fever vaccine
Brand name
ATC Code
J07BL01
Compare …

Yellow fever vaccine

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information is present at this moment.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Immunization against yellow fever
  • Subcutaneous
    • 6 months up to 9 months
      [1]
        • Children aged 6 to 9 months may only be vaccinated under special circumstances (e.g. during major outbreaks) and based on current official recommendations.
        • Children aged 6 months or more with HIV-positive mothers may be vaccinated if it has been shown that the child is not infected with HIV. Children who are infected with HIV may be vaccinated after consulting the HIV treating physicians and/or infectiologists.
    • ≥ 9 months
      [1]
      • 1.000 IU/dose, once only.

      • Administer at least 10 days before entering an endemically affected area:

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Very common (> 10%): irritability, loss of appetite, crying, drowsiness, pain at injection site, fever, vomiting

Common (1-10%): Erythema at site of injection and swelling at site of injection 

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications in children

Children younger than six months.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Children of ≥ 6 months with HIV-positive mothers may be vaccinated if it has been shown that they are not infected. If the child is HIV positive, consultation a paediatric team.

Live attenuated vaccines (e.g., yellow fever vaccine) should not be given to infants exposed to infliximab in utero until 12 months after birth. Administration of a live attenuated vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless serum levels of infliximab are undetectable in the infant. These infants may be at increased risk of infection, including severe disseminated infection that can become fatal. [DHPC]

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

VIRAL VACCINES

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

Encephalitis vaccines
J07BA02
J07BA01
Influenza vaccines
J07BB02
Hepatitis vaccines
J07BC20
J07BC02
J07BC01
Measles vaccines
J07BD52
Poliomyelitis vaccines
J07BF03
Rabies vaccines
J07BG01
Rota virus diarrhea vaccines
J07BH01
Varicella zoster vaccines
J07BK01
Papillomavirus vaccines
J07BM03
J07BM02
Other viral vaccines
J07BX04

References

  1. Sanofi Pasteur MSD, SmPC Stamaril (RVG17615) 04-12-2015, www.geneesmiddeleninformatiebank.nl
  2. Representatives of marketing authorisation holders of infliximab, DHPC Infliximab 07 maart 2022,, https://www.cbg-meb.nl/documenten/brieven/2022/03/08/dhpc-infliximab

Changes

Therapeutic Drug Monitoring


Overdose